Study guide
8.1 Anaemias, Haemostasis & Thrombosis
MRCPI in General Medicine Part I Written
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Strategy & Foundation
1.1 MRCPI Part I Format, Scoring & Standard-Setting 1.2 RCPI BST Curriculum & Single-Best-Answer Exam Strategy
2 Chapter 2: Cardiology & Vascular Medicine
2.1 Acute Coronary Syndromes & Stable Angina 2.2 Tachyarrhythmias, Bradyarrhythmias & Channelopathies 2.3 Heart Failure & Valvular Heart Disease 2.4 Hypertension, Vascular & Pericardial Diseases
3 Chapter 3: Respiratory Medicine
3.1 Asthma, COPD & Airway Diseases 3.2 Pneumonia, Tuberculosis & Respiratory Infections 3.3 Interstitial Lung Disease & Pleural Disorders 3.4 Pulmonary Embolism, Pulmonary Hypertension & Sleep Apnoea
4 Chapter 4: Gastroenterology & Hepatology
4.1 Upper & Lower GI Disorders & Inflammatory Bowel Disease 4.2 Acute & Chronic Liver Disease 4.3 Pancreatitis, Biliary Tract & GI Bleeding 4.4 Malabsorption, GI Motility & Clinical Nutrition
5 Chapter 5: Nephrology & Acid-Base Disorders
5.1 Acute Kidney Injury & Glomerular Diseases 5.2 Chronic Kidney Disease & Renal Replacement Therapy 5.3 Electrolyte Imbalances & Acid-Base Disorders
6 Chapter 6: Endocrinology & Diabetes
6.1 Diabetes Mellitus & Metabolic Complications 6.2 Thyroid & Calcium Disorders 6.3 Adrenal, Pituitary & Endocrine Syndromes
7 Chapter 7: Rheumatology & Clinical Immunology
7.1 Inflammatory Arthritides 7.2 Systemic Autoimmune & Vasculitic Diseases 7.3 Metabolic Bone Disease & Clinical Immunology
8 Chapter 8: Haematology & Medical Oncology
8.1 Anaemias, Haemostasis & Thrombosis 8.2 Leukaemias, Lymphomas & Plasma Cell Disorders 8.3 Medical Oncology & Oncological Emergencies
9 Chapter 9: Neurology & Dermatology
9.1 Stroke & Cerebrovascular Diseases 9.2 Epilepsy, Headache & Movement Disorders 9.3 Neuromuscular & Peripheral Nerve Disorders 9.4 Cutaneous Manifestations of Systemic Disease
10 Chapter 10: Acute Medicine, Critical Care & Geriatrics
10.1 Acute Poisoning & Toxidromes 10.2 Sepsis, Shock & Resuscitation 10.3 Geriatric Syndromes, Frailty & Comprehensive Care
11 Chapter 11: Clinical Pharmacology & Therapeutics
11.1 Pharmacokinetics & Pharmacodynamics 11.2 High-Risk Drug Classes & Prescribing Safety 11.3 Adverse Drug Reactions & Drug Safety
12 Chapter 12: Basic Sciences, Biostatistics & Clinical Ethics
12.1 Applied Cardiovascular & Respiratory Physiology 12.2 Clinical Biochemistry, Molecular Genetics & Microbiology 12.3 Biostatistics, Evidence-Based Medicine & Ethics
8.1 Anaemias, Haemostasis & Thrombosis
Key Takeaways Explain This Topic AI
Serum ferritin <30 µg/L possesses 92% sensitivity and 98% specificity for absolute iron deficiency, whereas ferritin up to 100 µg/L may still indicate iron deficiency in chronic inflammatory states.
Immune Thrombocytopenia (ITP) requires treatment when platelets fall below 30 x 10^9/L or in the presence of active mucosal bleeding, utilizing high-dose oral prednisolone (1 mg/kg/day) or IVIG (1 g/kg/day).
TTP is characterized by severe ADAMTS13 deficiency (<10% activity), presenting with microangiopathic haemolytic anaemia and thrombocytopenia requiring immediate plasma exchange and caplacizumab.
Unprovoked VTE requires at least 3 to 6 months of therapeutic anticoagulation followed by indefinite extended secondary prevention with DOACs (e.g., apixaban 2.5 mg BD) unless high bleeding risk supervenes.
Warfarin reversal for major life-threatening bleeding mandates immediate prothrombin complex concentrate (PCC 25-50 IU/kg) and intravenous phytomenadione (Vitamin K1 5-10 mg).
Last updated: July 2026
- 8.1 Anaemias, Haemostasis & Thrombosis
- Diagnostic Approach to Anaemias
Anaemia is defined by the World Health Organization (WHO) as a haemoglobin (Hb) concentration <130 g/L in men, <120 g/L in non-pregnant women, and <110 g/L in pregnant women. Initial evaluation requires classification based on the Mean Corpuscular Volume (MCV): microcytic (<80 fL), normocytic (80–100 fL), and macrocytic (>100 fL).
Microcytic Anaemia Differential Diagnostic Panel
The primary causes of microcytic anaemia are iron deficiency anaemia (IDA), anaemia of chronic disease (ACD), thalassaemia trait, and sideroblastic anaemia. Serum ferritin is the single most accurate test for iron deficiency; a level <30 µg/L confirms absolute iron deficiency, though acute phase reactant elevation in chronic illness can falsely elevate ferritin into the normal range (30–100 µg/L).
Diagnostic Parameter Iron Deficiency (IDA) Anaemia of Chronic Disease (ACD) Thalassaemia Trait Sideroblastic Anaemia
- Serum Ferritin Reduced (<30 µg/L) Normal or Elevated (>100 µg/L) Normal or Elevated Markedly Elevated
- Serum Iron Markedly Reduced Reduced Normal Elevated
- TIBC / Transferrin Elevated (>70 µmol/L) Reduced (<45 µmol/L) Normal Normal
- Transferrin Saturation Reduced (<15%) Reduced or Low-Normal (15–20%) Normal (>20%) Elevated (>50%)
- Mentzer Index (MCV/RBC) >13 >13 <13 Variable
- Hb Electrophoresis Normal Normal Elevated HbA2 (>3.5% in β-thal) Normal
MRCPI Exam Pearl: All men and postmenopausal women with newly diagnosed iron deficiency anaemia must undergo upper gastrointestinal endoscopy and colonoscopy to exclude occult gastrointestinal malignancy (e.g., colorectal carcinoma), regardless of bowel symptoms or dietary intake.
Macrocytic Anaemias: Megaloblastic vs. Non-Megaloblastic
Macrocytic anaemia is divided into megaloblastic (impaired DNA synthesis with nuclear-cytoplasmic asynchronous maturation) and non-megaloblastic causes:
Megaloblastic Anaemia: Vitamin B12 (cobalamin) deficiency and Folate deficiency. Characterized on blood film by hypersegmented neutrophils (≥5 lobes in >5% of neutrophils or ≥1 neutrophil with ≥6 lobes) and oval macrocytes.
Non-Megaloblastic Anaemia: Alcohol misuse, hypothyroidism, liver disease, reticulocytosis (haemolysis or acute blood loss), and myelodysplastic syndrome (MDS). Neutrophils display normal segmentation, and red cells are round.
In Vitamin B12 deficiency (pernicious anaemia, ileal resection, strict vegan diet), neurological complications include subacute combined degeneration of the spinal cord (SCD), affecting the posterior and lateral columns (loss of vibration/proprioception, upper motor neuron weakness, and extensor plantar responses). Vitamin B12 replacement must always precede or accompany folate repletion to prevent precipitating or worsening neurological degeneration.
Disorders of Primary & Secondary Haemostasis
Haemostasis involves primary haemostasis (platelet plug formation) and secondary haemostasis (coagulation cascade activation). Clinical presentation differs significantly: primary defects present with mucosal bleeding, petechiae, and epistaxis; secondary defects present with deep tissue haematomas and haemarthroses.
Coagulation Profiles & Clinical Correlations
Clinical Condition Prothrombin Time (PT) Activated Partial Thromboplastin Time (aPTT) Bleeding Time / PFA-100 Platelet Count
- Haemophilia A / B Normal Prolonged Normal Normal
- von Willebrand Disease (vWD) Normal Prolonged or Normal Prolonged Normal (except Type 2B)
- Warfarin / Vitamin K Deficiency Prolonged Prolonged Normal Normal
- Unfractionated Heparin (UFH) Prolonged Markedly Prolonged Normal Normal (unless HIT)
- Disseminated Intravascular Coagulation (DIC) Prolonged Prolonged Prolonged Markedly Reduced
- Immune Thrombocytopenia (ITP) Normal Normal Prolonged Reduced (<100 x 10^9/L)
- Thrombotic Microangiopathies: TTP vs. HUS
Thrombotic Thrombocytopenic Purpura (TTP) and Haemolytic Uraemic Syndrome (HUS) present with microangiopathic haemolytic anaemia (MAHA) with schistocytes on blood film and severe thrombocytopenia.
TTP: Mediated by severe deficiency of ADAMTS13 (<10% activity) due to autoantibodies. Classic pentad includes fever, MAHA, thrombocytopenia, neurological deficits, and renal impairment. Treatment is emergency plasma exchange (PEX), corticosteroid therapy, and anti-vWF monoclonal antibody caplacizumab . Platelet transfusions are strictly contraindicated as they precipitate microvascular thrombosis.
HUS: Shiga-toxin producing E. coli (STEC O157:H7) infection in children/adults, presenting with bloody diarrhoea, renal failure, and MAHA. ADAMTS13 levels are normal (>10%). Supportive care and hemodialysis are mainstay; plasma exchange is not routinely indicated.
Venous Thromboembolism (VTE) & Anticoagulation Management
Deep vein thrombosis (DVT) and pulmonary embolism (PE) management centers on prompt risk stratification using the Wells score and definitive diagnostic testing (D-dimer for low probability, CT pulmonary angiography [CTPA] or compression ultrasonography for high probability).
Direct Oral Anticoagulant (DOAC) Dosing & Reversal Agents
DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) are first-line agents for VTE treatment and non-valvular atrial fibrillation due to predictable pharmacokinetics and lack of routine monitoring requirements.
Drug Mechanism Standard VTE Treatment Renal Threshold / Adjustment Reversal Agent
Apixaban Direct Factor Xa Inhibitor 10 mg BD for 7 days, then 5 mg BD Reduce to 2.5 mg BD if CrCl 15–29 mL/min Andexanet alfa
Rivaroxaban Direct Factor Xa Inhibitor 15 mg BD for 21 days, then 20 mg OD Avoid if CrCl <15 mL/min Andexanet alfa
Dabigatran Direct Thrombin (IIa) Inhibitor LMWH lead-in 5 days, then 150 mg BD Avoid if CrCl <30 mL/min Idarucizumab
Warfarin Vitamin K Antagonist (II, VII, IX, X) Target INR 2.0–3.0 Safe in severe CKD / ESRD PCC + Vit K1
MRCPI Exam Pearl: For provoked VTE (transient risk factor such as surgery or trauma), anticoagulation is continued for 3 months. For unprovoked VTE or persistent risk factors (active cancer, antiphospholipid syndrome), extended long-term anticoagulation is indicated, provided bleeding risk is acceptable.